Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Achillion nets $41.7mm via RDO

Executive Summary

Infectious disease-focused Achillion Pharmaceuticals Inc. has netted $41.7mm through the sale of 6.4mm common shares at $6.57 (market average) to funds managed by QVT Financial LP. The money will support ongoing development of its lead hepatitis C candidates sovaprevir (ACH1625; Phase II), ACH2684 (Phase I), and ACH3102 (Phase I).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies